HK1253062A1 - Food supplement - Google Patents
Food supplement Download PDFInfo
- Publication number
- HK1253062A1 HK1253062A1 HK18112444.7A HK18112444A HK1253062A1 HK 1253062 A1 HK1253062 A1 HK 1253062A1 HK 18112444 A HK18112444 A HK 18112444A HK 1253062 A1 HK1253062 A1 HK 1253062A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- vitamin
- range
- extract
- nutritional supplement
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a food supplement which is provided, particularly for consumption or ingestion in the morning or in the evening. The invention also relates to a kit comprising two food supplements, wherein one of the food supplements is provided for consumption or ingestion in the morning and the other food supplement is provided for consumption or ingestion in the evening.
Description
Technical Field
The present invention relates to a nutritional supplement, preferably arranged for consumption in the morning or in the evening or for administration in the morning or in the evening. The invention also relates to a set comprising two nutritional supplement medicaments, of which one nutritional supplement medicament is arranged for consumption in the morning or for consumption in the morning and the other nutritional supplement medicament is arranged for consumption in the evening or for consumption in the evening.
Background
DE 102011008478 a1 relates to a physiologically effective, complete nutritional supplement which consists of a mixture of dried broccoli and dried vegetables and/or dried fruits. Preferably, a plant extract is added to the nutritional supplement, the plant extract consisting of pomegranate, caraway, seaweed, grape, hawthorn, witch hazel, arnica, nettle, calendula, propolis, elderberry, pineapple, horse chestnut, phaseolus vulgaris, allium ursinum, aloe, mucilage, garlic, ginseng, ginkgo biloba, and/or blackberry.
DE 102014118772 a1 discloses a mode of administration comprising two individuals a and B, which can be administered independently of one another, wherein the individuals a and B each comprise a mushroom component and furthermore comprise at least two further substances selected from natural substance extracts, vitamins and minerals, wherein the individuals a and B differ from one another on the basis of their composition. Preferred are plant extracts selected from the group consisting of: rose hip extract, black cherry extract, hawthorn fruit extract, yam extract, soybean extract, safflower alfalfa extract, ginseng extract, rhodiola rosea extract, artichoke extract, fennel extract, and ginkgo biloba extract, bamboo shoot extract, oat extract, nettle extract, broccoli extract, and mixtures consisting of two or more thereof.
DE 102015009525 a1 discloses a nutritional supplement which comprises or consists of phytoestrogens or phytoestrogen metabolites in combination with theanine and, if desired, customary excipients. The nutraceutical includes extracts composed of plants and plant derivatives, such as Ackermennig, alfalfa, aloe, amaranth, Angelica sinensis, anise, barberry, basil, fruits of bay, pear powder, birch, bistort, blackberry, black cohosh, black walnut, thistle, motherwort, blue verbena, marijuana, borage, geranium, buckthorn, rhizome of rehmannia, burdock, bell pepper, caraway, cascara, catnip, celery, cornflower, chrysanthemum, chamomile, chickweed, chicory root, cinchona bark, clove, coltsfoot, comfrey, stigma Maydis, cockaya, cogongrass, Culverwurzel, cornflower, DAMI ANA leaf, dandelion, vetiver grass, Angelica sinensis, echinacea, ash bark, ephedra, eucalyptus, evening primrose, millet grass, common sage, fennel, fenugreek, flaxseed, garlic, sage, etc, Ginger, ginseng, marrubium vulgare, centella asiatica, gelidium officinale, hawthorn, hops, peppermint, horseradish, horsetail, polygonum multiflorum, hydrangea, hyssop, lichen islandica, irish moss, jojoba oil, juniper, kelp, cypress, lemon grass, licorice root, Chinese lobelia, mandshula, marigold, marjoram, hollyhock, mistletoe, verbena, mustard, myrrh, nettle, oat straw, mahonia, papaya, parsley, passion fruit, peach seed, spearmint, peppermint, ivy, plantain, bird nest, poke root, poke, ash, plantain seed, quassia, purpurpurpurpus, trifoliate, raspberry, sodium bentonite, rhubarb, rosehip, rosemary, safflower, saffrond, sage, hypericum, sasanqua, scutellaria, senega, sargent, sasanqua, sage, elm, mucilage, sage, elm, sage, etc Green mint, giant shrub, partridge berry, Stillingie, strawberry, pau d' arco, thyme, bearberry, valerian, violet, watercress, white pine, wild cherry, oak lettuce, yam, willow, cranberry, witch hazel, red stachys, wormwood, yarrow, krausser Ampfer, bear, yucca, and combinations thereof.
DE 202011105533U 1 discloses a vitamin composition according to the nutritional concept of asia and mediterranean, comprising vitamins, trace elements and omega-3-fatty acids, wherein the components are present in at least two separate contributions of different components, wherein the first contribution comprises as a further effective component at least one extract selected from the group comprising vine extract, olive extract and/or tomato extract, and wherein the second contribution comprises as a further effective component at least one extract selected from the group comprising wolfberry extract, ginger extract and/or green tea extract.
EP 1781330B 1 relates to a composition with a capillary-active system having application-related microtablity and synergistic potential for use in mammals, especially humans. Particularly preferred compositions comprise one or more substances as the drug of system S1, said substances being selected from the following: cysteine, methionine, biotin, zinc oxide, thiamine (B1), calcium pantothenate (B5), silicon dioxide; the drug used as system S2 is ginseng, brazil nut, motherwort, amino acid or a mixture thereof; the drug as system S3 is a plant extract such as green tea, echinacea, schisandra, astragalus, ganoderma lucidum, shiitake mushroom, corn, caramel, soybean, ternate buttercup, grape seed, broccoli, tomato, onion, cauliflower, citrus-bioflavonoids, buckwheat, or grapefruit. Also preferred are the following ingredients, wherein the catalyst system KAL-arginine-hydrochloride, protectant system KP drug is selected from the following group KP: folic acid, vitamin B6-HCL (B6), cyanocobalamin (B12), tocopherol (E), grape seed oil and/or gallon seed oil; and the drugs in group KE are selected from Q10, niacinamide (niacin, B3) or mixtures thereof.
WO 01/50886 a1 relates to a non-dairy instant powder comprising fructooligosaccharides and at least one additional component selected from minerals, trace elements and plant extracts. Preferred herb extracts and/or fruit extracts are rosemary extract, gentian extract, teal root extract, ginseng extract, chrysanthemum extract, linden tea extract, nepeta cataria leaf extract, hop extract, soapberry extract, dill fruit-containing extract, hibiscus extract, rose hip extract, lavender extract and citrus peel extracts, such as lemon peel and/or orange peel extract and/or tea extract, such as black tea extract, green tea extract and mate tea extract.
WO 02/067986 a2 discloses a regenerable drug comprising (a) a microbial component comprising: (a1) at least one nonpathogenic microorganism and/or (a2) at least one pathogenic or selective pathogenic microorganism; (b) a modulator component comprising (b1) at least one enzyme; (b2) at least one GRAS (generally recognized as safe) fragrance material or derivative thereof and/or (b3) at least one animal or plant extract or derivative thereof, said extract/derivative comprising a linkage to an alcohol, acid, ester, aldehyde, acetal, phenol, functional group and/or a linkage with a double bond. Here, it is particularly preferred that the extract is or comprises the following raw materials: aloe vera, annatto (seed), arnica, valerian, gromwell, birch leaf, pollen, nettle, mushroom, dill, ivy, kapok, oak (bark), spruce (needle), ginkgo (leaf), ginseng (root), witch hazel (leaf) reddish brown, dried grass flower, hibiscus flower, hop, coltsfoot, ginger (root), holy john's wort, cocoa bean, coffee bean, chamomile, carrot, garlic, kola, caraway, fennel, lavender, lime (flower), dandelion, mallow, kola, fennel, lavender, lime (flower), dandelion, mallow,marjoram, melissa, tangerine (pericarp), orthophos, capsicum, pepper, mint, mushroom, rhubarb, calendula, rosemary, horse chestnut, sage, horsetail, celandine, black tea, licorice, juniper (berry), hawthorn, wheat bran, cinnamon, algae, banana, Benzo, birch tar, Bochshorn, boldo leaves, chinaroot greenbrier, Copai-Balsam, deriswurzel, cajeput oil, gentian, eucalyptus, fennel, bogbean, calamus, potato starch, pine rosin, onion, peppermint, pine,linseed, bay leaf, pine tar, Niduli-Baum, balsam of Peru, pyrethrum, quassia, rice, rotenone, and the like,Saponin, salsify, mustard, sesame, soybean, chrysanthemums, cornflower, turpentine, plantain, white reed, wormwood, cypress, apple, avocado, cocoa, grapefruit, melon, cucumber, oat, wax gourd, jojoba oil, kiwi, burdock, clover, coconut, corn flower, almond, mango, mistletoe, yew, papaya, passion fruit, peach, yarrow, primrose, sunflower, dead nettle, thyme, walnut, peppermint, ylang-ylang, cochineal carmine, beeswax, royal jelly, propolis, shellac, lecithin, formate, formic acid, lutein, canthaxanthin, riboflavin, fatty acids and derivatives, angora, Astrahan, cashmere, mohair, wool, raw milk, casein, Kasei pi ogpen, bienenglenol, egg-nengfift, bee pollen, placenta, kalin, whey, amber, meat, amber, egg white fish, lotus, etc Capiz, caviar, chitin, coral, squalene, seal, whale oil, sponge, pearl, roe, whale oil, shellfish,Wax, Karmine, carminic acid, catgut, musk, civet, castor oil, estrogen, progesterone, tester, hormone, ivory, lanolin, mink oil, parchment, silk, snake venom, urea, amino acid, meat jelly, bone, Borsten, collagen, down, blood, gelatin, glycerin, fur, leather, oil stearin, rennin, and stearin extract.
WO 2013/152055 a1 relates to a composition for mitigating radiation-induced effects from life shortening and consequences of oxidative stress relative to radiation source exposure, wherein the radiation oxidative exposure treatment composition comprises: a mixture of micronutrients, multivitamins and trace elements, a mixture of antioxidants and chemotherapeutic agents and, if desired, fatty acids.
WO 2015/014497 a1 relates to an edible product, wherein the product comprises a layer consisting of a fibrous plant product and a plant extract coated thereon.
The nutritional supplements known in the prior art are not satisfactory in every respect and there is a need for improved nutritional supplements.
Disclosure of Invention
It is an object of the present invention to provide a nutraceutical which has advantages over the prior art.
This object is solved by the subject matter of the claims of the present application.
A first aspect of the invention relates to a nutritional supplement comprising:
(a) a mineral component;
(b) a vitamin component; and
(c) a plant extract component.
It has been surprisingly found that the nutritional supplement according to the invention has advantages in terms of occurrence of headache, nausea, health, free deep breathing, eye inflammation and working ability, especially from subjects who are trying to live in urban living areas and are therefore sometimes more contaminated with air. These advantages have been registered with research/application observations and the results are statistically significant.
For purposes of this description, all percentage indications are expressed in weight percent (wt%), unless explicitly stated otherwise. The expression "and/or" between element a and element B means: (i) only element a, but not both, element B; (ii) only element B, but not both element A; or (iii) there is an element A and also an element B.
The mineral component of the nutritional supplement of the present invention comprises at least one physiologically digestible salt comprising:
-a cation selected from the group consisting of: calcium, cobalt, iron, potassium, copper, magnesium, manganese, molybdenum, vanadium and zinc; and
-an anion selected from the group consisting of: acetates, carbonates, chlorides, fluorides, gluconates, iodates, iodides, oxalates, oxides, phosphates, phosphonates, and sulfates; and
preferably, the mineral component comprises a physiologically digestible zinc salt, particularly preferably zinc sulfate, especially zinc sulfate hydrate, and/or a physiologically digestible magnesium salt, particularly preferably magnesium carbonate and/or a physiologically digestible iron salt, particularly preferably iron gluconate.
The vitamin component of the nutritional supplement of the present invention comprises at least one vitamin selected from the group consisting of: vitamin a (retinol), vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B4 (adenine, choline), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B7 (biotin), vitamin B8 (adenosine phosphate), vitamin B9 (folic acid), vitamin B10 (p-aminobenzoic acid, mixture of vitamin B groups), vitamin B11 (folic acid), vitamin B12 (cobalamin), vitamin B13 (orotic acid), vitamin B14 (mixture of vitamin B10 and B11), vitamin B15 (pangamine), vitamin B16 (pyridoxine), vitamin B17 (mandelic acid), vitamin B22, vitamin BT (levocarnitine), vitamin BX (p-aminobenzoic acid), vitamin C (ascorbic acid), vitamin D (calcium ascorbate), vitamin D (calcium), Vitamin E (tocopherol), vitamin H (biotin), vitamin K (phylloquinone, menaquinone), vitamin Q (ubiquinone, coenzyme Q10) and their derivatives, preferably tocopherol acetate, riboflavin-5-carbonate.
In a preferred embodiment, the vitamin component comprises vitamin B2 and/or a vitamin B2 derivative (preferably riboflavin-5-carbonate) and/or vitamin C and/or vitamin E and/or a vitamin E derivative (preferably alpha tocopheryl acetate) and/or vitamin Q (ubiquinone, coenzyme Q10). Coenzyme Q10 is understood according to the invention to be a vitamin.
the plant extract component of the nutritional supplement of the present invention comprises at least one plant extract, preferably at least two plant extracts, more preferably at least three plant extracts, wherein the plant extracts are each an extract from a plant or plant part selected from the group consisting of horsetail grass, calendula, inula flower, aloe, anise, arnica, artichoke, eyebright herb, valerian, bearberry leaf, mugwort, lithospermum, birch leaf, Bifskraut, alfalfa, quassia, plantago latifolia, nettle, echinacea, ivy, kapok, pine bark, angelica, gentian, eucalyptus, sea buckthorn bark, fennel, meadowfoam, wormwood, ginkgo biloba, ginseng, cane, green tea, witch hazel, formononetin, white moss, blueberry leaf, camelina, shepherd's purse, elderberry, hondri, holly, chamomile, plantain, japanese sage,shallot, lemon balm, mistletoe,Turnip, olive oil, passion flower, petasites japonicus, peppermint, rhubarb extract, marigold, fruit castor, rosemary, horse chestnut,fructte, sage, sea buckthorn, horsetail, yarrow, lotus, celandine, senna, echinacea, sundew, plantain, clover, sage, licorice, cornflower, datura, thyme, Tormentill, grape skin, black cohosh, juniper, walnut, plantain, chicory, hawthorn, wormwood, witch hazel and onionUnder wood juice powder is understood a plant extract.
Preferably, the plant extract component comprises at least two, preferably at least three, different plant extracts, respectively extracts from plants or plant parts, selected independently of each other from the group consisting of: echinacea, ginseng, green tea, elderberry, sage and grape skin.
In a preferred embodiment, the plant extract component comprises ginseng extract and/or green tea extract and/or grape skin extract and/or echinacea extract and/or elderberry extract (elderberry juice powder) and/or sage leaf extract.
The weight share of the plant extract component is preferably in the range of 0.010 to 5.000 weight%, more preferably in the range of 0.015 to 4.000 weight%, more preferably in the range of 0.020 to 3.000 weight%, still more preferably in the range of 0.025 to 2.000 weight%, most preferably in the range of 0.030 to 1.500 weight% and especially in the range of 0.035 to 1.200 weight%, respectively, based on the total weight of the nutritional supplement.
In a preferred embodiment, the nutritional supplement of the present invention further comprises:
(d) a sweet substance component; and/or
(e) An acid species component; and/or
(f) And (4) an essence component.
In a preferred embodiment, the nutritional supplement of the present invention comprises or consists of: (a) (ii), (b) and (c); or (a), (b), (c) and (d); or (a), (b), (c) and (e); or (a), (b), (c) and (f); or (a), (b), (c), (d) and (e); or (a), (b), (c), (d), and (f); or (a), (b), (c), (e) and (f); or (a), (b), (c), (d), (e) and (f).
The weight share of the sweetener component is preferably at least 50% by weight, based on the total weight of the nutritional supplement medicament.
The weight share of the plant extract component is preferably in the range of 0.01 to 5.0 wt. -%, based on the total weight of the nutritional supplement medicament.
The sweetener component of the nutraceutical of the present invention preferably includes:
-at least one carbohydrate selected from the group consisting of: sucrose, glucose syrup, invert sugar, fructose, and maltose; and/or
-at least one sweetener selected from the group consisting of: acesulfame K, alitame, aspartame-acesulfame K, sweet proteins, cyclamate, dulcin, hernandulcin, guanidinoacetic acid, monellin, neohesperidin, neotame, pentadin, saccharin, sucralose, stevioside, thaumatin; and/or
-at least one sugar substitute selected from the group consisting of: sorbitol, mannitol, isomalt, maltitol syrup, lactitol, xylitol and erythritol.
In a preferred embodiment, the nutritional supplement of the invention does not comprise a sugar substitute.
The weight share of the sweetener component is preferably at least 50 wt. -%, more preferably at least 60 wt. -%, more preferably at least 70 wt. -%, still more preferably at least 75 wt. -%, most preferably at least 80 wt. -%, and especially at least 85 wt. -%, based on the total weight of the nutritional supplement medicament, respectively.
The sweetener component includes at least two carbohydrates and/or at least two sweeteners. Particularly preferred sweetener components include sucrose, maltol, aspartame and acesulfame k.
The acidulant component of the nutritional supplement of the present invention preferably includes at least one carboxylic acid selected from the group consisting of: citric acid, tartaric acid and malic acid.
Preferably, the acid material component comprises citric acid.
The flavor component of the nutritional supplement of the present invention preferably comprises at least one flavor selected from the group consisting of: pineapple, apple, apricot (Marille), banana, pear, blackberry, strawberry, grapefruit, raspberry, cherry, kiwi, lemon, mango, citrus, melon, orange, papaya, passion fruit (Maracuja), peach, plum, quince, blackcurrant, gooseberry, tropical fruit, and lemon.
Preferably, the flavour component comprises tropical flavour and/or lemon flavour and/or orange flavour.
In a particularly preferred embodiment, the nutritional supplement of the invention (hereinafter referred to as "morning care nutritional supplement"):
(a) the mineral component comprises a physiologically digestible zinc salt; and/or
(b) Vitamin component
-vitamin B2 or a vitamin B2 derivative, preferably riboflavin-5-carbonate,
-vitamin C, and
-vitamin E or a vitamin E derivative, preferably alpha-tocopheryl acetate; and/or
(c) The plant extract component comprises Ginseng radix extract, green tea extract and grape skin extract; and/or
(f) The flavor component comprises tropical flavor.
Preferably, in the morning care nutritional supplement of the present invention, the total weight of the nutritional supplement,
the weight fraction of the physiologically digestible zinc salt is in the range of 0.033 ± 0.030 wt.%, even more preferably in the range of 0.033 ± 0.025 wt.%, most preferably in the range of 0.033 ± 0.020 wt.% and in particular in the range of 0.033 ± 0.015 wt.%; and/or
The weight share of vitamin B2 or vitamin B2 derivative is in the range of 0.0010 ± 0.0008 wt.%, more preferably in the range of 0.0010 ± 0.0007 wt.%, still more preferably in the range of 0.0010 ± 0.0006 wt.%, most preferably in the range of 0.0010 ± 0.0005 wt.% and in particular in the range of 0.0010 ± 0.0004 wt.%; and/or
The weight share of vitamin C is in the range of 1.067 ± 1.000 wt. -%, more preferably in the range of 1.067 ± 0.800 wt. -%, still more preferably in the range of 1.067 ± 0.600 wt. -%, most preferably in the range of 1.067 ± 0.400 wt. -% and in particular in the range of 1.067 ± 0.2000 wt. -%; and/or
The weight share of vitamin E or vitamin E derivative is in the range of 0.080 ± 0.070 wt. -%, more preferably in the range of 0.080 ± 0.060 wt. -%, still more preferably in the range of 0.080 ± 0.050 wt. -%, most preferably in the range of 0.080 ± 0.040 wt. -% and especially in the range of 0.080 ± 0.030 wt. -%; and/or
-the weight share of the ginseng extract is in the range of 0.167 ± 0.150 wt. -%, more preferably in the range of 0.167 ± 0.130 wt. -%, yet more preferably in the range of 0.167 ± 0.110 wt. -%, most preferably in the range of 0.167 ± 0.090 wt. -% and especially in the range of 0.167 ± 0.070 wt. -%; and/or
-the weight share of the green tea extract is in the range of 0.083 ± 0.080 wt. -%, more preferably in the range of 0.083 ± 0.070 wt. -%, yet more preferably in the range of 0.083 ± 0.060 wt. -%, most preferably in the range of 0.083 ± 0.050 wt. -% and especially in the range of 0.083 ± 0.040 wt. -%; and/or
The weight share of the grape skin extract is in the range of 0.167 ± 0.150 wt.%, more preferably in the range of 0.167 ± 0.130 wt.%, still more preferably in the range of 0.167 ± 0.110 wt.%, most preferably in the range of 0.167 ± 0.090 wt.% and especially in the range of 0.167 ± 0.070 wt.%.
Preferably, in the morning care nutritional supplement of the invention, the total content is based in each case on: zinc salt, vitamin B2 or its derivative, vitamin C, vitamin E or its derivative, Ginseng radix extract, green tea extract and grape skin extract,
the weight fraction of the physiologically digestible zinc salt is in the range of 2.1 ± 2.0 wt. -%, yet more preferably in the range of 2.1 ± 1.5 wt. -%, most preferably in the range of 2.1 ± 1.0 wt. -% and in particular in the range of 2.1 ± 0.5 wt. -%; and/or
The weight share of vitamin B2 or vitamin B2 derivative is in the range of 0.10 ± 0.08% by weight, more preferably in the range of 0.10 ± 0.07% by weight, still more preferably in the range of 0.10 ± 0.06% by weight, most preferably in the range of 0.10 ± 0.05% by weight and in particular in the range of 0.10 ± 0.04% by weight; and/or
The weight share of vitamin C is in the range of 1.067 ± 1.000 wt. -%, more preferably in the range of 1.067 ± 0.800 wt. -%, still more preferably in the range of 1.067 ± 0.600 wt. -%, most preferably in the range of 1.067 ± 0.400 wt. -% and in particular in the range of 1.067 ± 0.2000 wt. -%; and/or
The weight share of vitamin E or vitamin E derivative is in the range of 5.0 ± 4.0 wt.%, more preferably in the range of 5.0 ± 3.2 wt.%, still more preferably in the range of 5.0 ± 2.4 wt.%, most preferably in the range of 5.0 ± 1.6 wt.% and in particular in the range of 5.0 ± 0.8 wt.%; and/or
-the weight share of the ginseng extract is in the range of 10.4 ± 10.0 wt. -%, more preferably in the range of 10.4 ± 8.0 wt. -%, yet more preferably in the range of 10.4 ± 6.0 wt. -%, most preferably in the range of 10.4 ± 4.0 wt. -% and especially in the range of 10.4 ± 2.0 wt. -%; and/or
-the weight share of the green tea extract is in the range of 5.2 ± 5.0 wt. -%, more preferably in the range of 5.2 ± 4.0 wt. -%, yet more preferably in the range of 5.2 ± 3.0 wt. -%, most preferably in the range of 5.2 ± 2.0 wt. -% and especially in the range of 5.2 ± 1.0 wt. -%; and/or
The weight fraction of the grape skin extract is in the range of 10.4 ± 10.0 wt. -%, more preferably in the range of 10.4 ± 8.0 wt. -%, still more preferably in the range of 10.4 ± 6.0 wt. -%, most preferably in the range of 10.4 ± 4.0 wt. -% and especially in the range of 10.4 ± 2.0 wt. -%.
Preferably, in the morning care nutritional supplement of the invention, in each case based on the total amount of the nutritional supplement which is set for administration, preferably administration in the morning,
-the physiologically digestible zinc salt is comprised in a dose in the range of 5.0 ± 4.0mg, still more preferably in the range of 5.0 ± 3.0mg, most preferably in the range of 5.0 ± 2.0mg and especially in the range of 5.0 ± 1.0 mg; and/or
Vitamin B2 or a vitamin B2 derivative in an amount comprised in the range of 0.21 ± 0.20mg, more preferably in the range of 0.21 ± 0.16mg, still more preferably in the range of 0.21 ± 0.12mg, most preferably in the range of 0.21 ± 0.08mg and especially in the range of 0.21 ± 0.04 mg; and/or
-vitamin C is comprised in a dose in the range of 160 ± 150mg, more preferably in the range of 160 ± 120mg, still more preferably in the range of 160 ± 90mg, most preferably in the range of 160 ± 60mg and especially in the range of 160 ± 30 mg; and/or
-vitamin E or a vitamin E derivative is comprised in a dose in the range of 12 ± 10mg, more preferably in the range of 12 ± 8mg, still more preferably in the range of 12 ± 6mg, most preferably in the range of 12 ± 4mg and especially in the range of 12 ± 2 mg; and/or
-the ginseng extract comprises a dose in the range of 25 ± 24mg, more preferably in the range of 25 ± 18mg, still more preferably in the range of 25 ± 12mg, most preferably in the range of 25 ± 8mg and especially in the range of 25 ± 4 mg; and/or
-the green tea extract comprises a dose in the range of 12.5 ± 10mg, more preferably in the range of 12.5 ± 8mg, still more preferably in the range of 12.5 ± 6mg, most preferably in the range of 12.5 ± 4mg and especially in the range of 12.5 ± 2 mg; and/or
-the grape skin extract comprises a dose in the range of 25 ± 24mg, more preferably in the range of 25 ± 18mg, still more preferably in the range of 25 ± 12mg, most preferably in the range of 25 ± 8mg and especially in the range of 25 ± 4 mg.
Preferably, the morning care nutritional supplement of the present invention is configured for consumption in the morning or is configured for consumption in the morning.
In another particularly preferred embodiment, the nutritional supplement of the invention (hereinafter referred to as "evening primrose nutritional supplement"):
(a) the mineral component comprises a physiologically digestible magnesium salt and a physiologically digestible iron salt; and/or
(b) The vitamin component comprises vitamin Q; and/or
(c) The plant extract components comprise Echinacea purpurea extract, elderberry extract and Salvia officinalis leaf extract; and/or
(f) The essence components comprise lemon essence and orange essence.
Preferably, in the evening primrose nutritional supplement of the invention, the amount of the total weight of the nutritional supplement,
the weight proportion of the physiologically digestible magnesium salt is in the range of 0.667 ± 0.600 wt.%, more preferably in the range of 0.667 ± 0.500 wt.%, still more preferably in the range of 0.667 ± 0.400 wt.%, most preferably in the range of 0.667 ± 0.300 wt.% and in particular in the range of 0.667 ± 0.200 wt.%; and/or
The weight fraction of the physiologically digestible iron salt is in the range of 0.033 ± 0.030 wt. -%, more preferably in the range of 0.033 ± 0.025 wt. -%, still more preferably in the range of 0.033 ± 0.020 wt. -%, most preferably in the range of 0.033 ± 0.015 wt. -% and in particular in the range of 0.033 ± 0.010 wt. -%; and/or
The weight fraction of vitamin Q is in the range of 0.033 ± 0.030 wt.%, more preferably in the range of 0.033 ± 0.025 wt.%, still more preferably in the range of 0.033 ± 0.020 wt.%, most preferably in the range of 0.033 ± 0.015 wt.% and in particular in the range of 0.033 ± 0.010 wt.%; and/or
The weight share of the echinacea extract is in the range of 0.333 ± 0.300 wt. -%, more preferably in the range of 0.333 ± 0.250 wt. -%, still more preferably in the range of 0.333 ± 0.200 wt. -%, most preferably in the range of 0.333 ± 0.150 wt. -% and especially in the range of 0.333 ± 0.100 wt. -%; and/or
-the weight share of the elderberry extract is in the range of 0.480 ± 0.450 wt. -%, more preferably in the range of 0.480 ± 0.400 wt. -%, still more preferably in the range of 0.480 ± 0.350 wt. -%, most preferably in the range of 0.480 ± 0.300 wt. -% and especially in the range of 0.480 ± 0.250 wt. -%; and/or
The weight share of the sage leaf extract is in the range of 0.333 ± 0.300 wt.%, more preferably in the range of 0.333 ± 0.250 wt.%, still more preferably in the range of 0.333 ± 0.200 wt.%, most preferably in the range of 0.333 ± 0.150 wt.% and especially in the range of 0.333 ± 0.100 wt.%.
Preferably, in the evening primrose supplement of the invention, in each case based on the total content of: magnesium salt, ferric salt, vitamin Q, Echinacea purpurea extract and folium Salvia officinalis,
the weight fraction of the physiologically digestible magnesium salt is in the range of 47.6 ± 45.0 wt.%, more preferably in the range of 47.6 ± 36.0 wt.%, still more preferably in the range of 47.6 ± 27.0 wt.%, most preferably in the range of 47.6 ± 18.0 wt.% and in particular in the range of 47.6 ± 9.0 wt.%; and/or
The weight fraction of the physiologically digestible iron salt is in the range of 2.4 ± 2.0 wt. -%, more preferably in the range of 2.4 ± 1.6 wt. -%, still more preferably in the range of 2.4 ± 1.2 wt. -%, most preferably in the range of 2.4 ± 0.8 wt. -% and in particular in the range of 2.4 ± 0.4 wt. -%; and/or
The weight fraction of vitamin Q is in the range of 2.4 ± 2.0 wt. -%, more preferably in the range of 2.4 ± 1.6 wt. -%, yet more preferably in the range of 2.4 ± 1.2 wt. -%, most preferably in the range of 2.4 ± 0.8 wt. -% and in particular in the range of 2.4 ± 0.4 wt. -%; and/or
The weight share of the echinacea extract is in the range of 23.8 ± 20.0 wt. -%, more preferably in the range of 23.8 ± 16.0 wt. -%, still more preferably in the range of 23.8 ± 12.0 wt. -%, most preferably in the range of 23.8 ± 8.0 wt. -% and especially in the range of 23.8 ± 4.0 wt. -%; and/or
The weight share of the sage leaf extract is in the range of 23.8 ± 20.0 wt. -%, more preferably in the range of 23.8 ± 16.0 wt. -%, still more preferably in the range of 23.8 ± 12.0 wt. -%, most preferably in the range of 23.8 ± 8.0 wt. -% and especially in the range of 23.8 ± 4.0 wt. -%.
Preferably, in the evening primordial nutritional supplement of the invention, in each case based on the total amount of the nutritional supplement which is provided for administration, preferably for administration in the evening,
-the physiologically digestible magnesium salt comprises a dose in the range of 100 ± 80mg, more preferably in the range of 100 ± 72mg, still more preferably in the range of 100 ± 54mg, most preferably in the range of 100 ± 36mg and especially in the range of 100 ± 18 mg; and/or
-the physiologically digestible iron salt is comprised in a dose in the range of 5.0 ± 4.0mg, more preferably in the range of 5.0 ± 3.2mg, still more preferably in the range of 5.0 ± 2.4mg, most preferably in the range of 5.0 ± 1.6mg and especially in the range of 5.0 ± 0.8 mg; and/or
Vitamin Q is comprised in a dose in the range of 5.0 ± 4.0mg, more preferably in the range of 5.0 ± 3.2mg, still more preferably in the range of 5.0 ± 2.4mg, most preferably in the range of 5.0 ± 1.6mg and especially in the range of 5.0 ± 0.8 mg; and/or
-the echinacea extract comprises a dose in the range of 50 ± 40mg, more preferably in the range of 50 ± 32mg, still more preferably in the range of 50 ± 24mg, most preferably in the range of 50 ± 16mg and especially in the range of 50 ± 8 mg; and/or
-the sage leaf extract is comprised in a dose in the range of 50 ± 40mg, more preferably in the range of 50 ± 32mg, still more preferably in the range of 50 ± 24mg, most preferably in the range of 50 ± 16mg and especially in the range of 50 ± 8 mg.
Preferably, the evening primordial supplement of the invention is arranged for consumption in the evening or is arranged for administration in the evening.
The nutritional supplement of the invention is preferably present as a powder, but may also be present, for example, in the form of a compressed tablet, for example, in the form of a tablet or effervescent tablet.
The nutritional supplement of the invention is packaged as individual units that are arranged for consumption or are arranged for administration.
Preferably, the amount provided for consumption or provided for administration, respectively, is in the range of 5g to 100g, more preferably in the range of 5g to 25g, based on the total weight of the nutritional supplement medicament.
Preferred individual units have a total weight in the range of 15 ± 12g, more preferably in the range of 15 ± 10g, still more preferably in the range of 15 ± 8g, most preferably in the range of 15 ± 6mg and especially in the range of 25 ± 4 g.
Preferably, the nutritional supplement of the invention has a physiological caloric value per 100g in the range of 1625 ± 1600kJ, more preferably in the range of 1625 ± 1300kJ, still more preferably in the range of 1625 ± 1000kJ, most preferably in the range of 1625 ± 700kJ and especially in the range of 1625 ± 400 kJ.
Preferably, the nutritional supplement according to the invention has a fat content of at most 2.5 wt. -%, more preferably at most 0.5 wt. -%, still more preferably at most 0.25 wt. -%, most preferably at most 0.10 wt. -% and especially at most 0.05 wt. -%, based on the total weight.
Preferably, the nutritional supplement of the invention has a protein content of at most 2.5 wt. -%, more preferably at most 0.5 wt. -%, still more preferably at most 0.25 wt. -%, most preferably at most 0.10 wt. -% and especially at most 0.05 wt. -%, based on the total weight.
Preferably, the nutritional supplement of the present invention does not contain table salt.
Another aspect of the present invention relates to a kit comprising at least one morning protection nutritional supplement of the present invention described above and at least one evening restoration nutritional supplement of the present invention described above.
Another aspect of the present invention relates to a nutritional supplement of the invention as described above,
(i) for use in the prevention of illnesses or in the treatment of headaches,
(ii) for use in the prophylaxis of illnesses or in the management of nausea,
(iii) for use in the prevention of disease or the treatment of ocular inflammation,
(iv) is used for improving health of patients with diabetes,
(v) for improving free deep breathing, or
(vi) For improving the workability.
Detailed Description
The invention is further illustrated by the following examples. However, these embodiments should not be designed restrictively:
example 1:
powder mixtures having a total weight of 15000mg and the following ingredients, respectively, have been produced:
morning protection nutrition supplement:
evening recovery of nutritional supplements:
| sucrose | I | Sweetening agent | |||
| Citric acid | I | Sour agent | |||
| Malt saccharin | I | ||||
| Magnesium carbonate | A | 100.00 | mg | Magnesium alloy | |
| Sambucus williamsii fruit juice powder | I | 72.00 | mg | Sambucus williamsii fruit juice powder | |
| Coenzyme Q10 | A | 5.00 | mg | Coenzyme Q10 | |
| Echinacea purpurea extract | A | 50.00 | mg | Echinacea purpurea extract | |
| Salvia officinalis leaf extract | A | 50.00 | mg | Salvia officinalis leaf extract | |
| Calcium iron gluconate | A | 5.00 | mg | Iron | |
| Lemon essence | I | Essence | |||
| Orange essence | I | Essence | |||
| Aspartame | I | Sweetening agent | |||
| Acesulfame K | I | mg | Vitamin B2 | Sweetening agent |
I: physiologically inactive; a: is physiologically active.
Example 2:
over the course of 2 months of study/application observations, 79 subjects had been examined. Prior to the start and after expiration of the eight week dosing period, questionnaires were presented to subjects (all subjects with urban residences with partially elevated emission values). In this case, the subject must answer questions about health, coughing, ability to work, ability to breathe freely and deeply, and possibly also aesthetics. Furthermore, heart rate and oxygen saturation have been measured by means of the fingernails before and after the application period.
During an observation period of eight weeks, subjects were each administered a full teaspoon, as per example 1 (morning and evening application), formulated to dissolve in a glass of water.
A total of 79 subjects were recorded into the study. The subjects were aged from 18 to 83 years with age spikes of 21-40 years (a first group recruited a panel of students) and 61-80 years (a second group recruited from hospital patients with different advanced disease). Especially the last mentioned advanced diseases or risks of patients have been Chronic Obstructive Pulmonary Disease (COPD) or asthmatic bronchitis or long-standing abuse of nicotine.
The values of the features to be queried have been statistically compared by means of a paired t-test. The wilcoxon test was applied exclusively when observing SpO2 values, since here it is possible to distribute it non-normally.
The results are summarized below:
headache:
the results are also shown in fig. 1A to 1C (left, right, respectively).
Nausea:
the results are also shown in fig. 2 (left first, right second).
Health:
the results are also shown in fig. 3 (left first, right second).
The working capacity is as follows:
the results are also shown in fig. 4 (left first, right second).
Deep breathing:
the results are also shown in fig. 5 (left first, right second).
Cough:
the results are also shown in fig. 6 (left first, right second).
Eye inflammation:
the results are also shown in fig. 7 (left first, right second).
Peripheral oxygen saturation (SpO2) and heart rate (HF):
the results are also shown in fig. 8 (left first, right second).
In summary, in the following tables for each parameter, the significance level (p <0.05 means statistically significant) and the corresponding mean values and relative percentage changes of the preceding (first value) and the following (second value) are summarized:
| previously described | After that | |||
| Mean value of headache | p<0,005 | 2,73417722 | 1,93670886 | -29,2％ |
| Maximum headache | p<0,005 | 4,16455696 | 3,08860759 | -25,8％ |
| Frequency of headache | p<0,005 | 2,10126582 | 1,50632911 | -28,3％ |
| Mean value of nausea | p<0,005 | 1,30379747 | 0,83544304 | -35,9％ |
| Average value of health | p<0,005 | 6,6835443 | 7,16455696 | 7,2％ |
| Average value of working ability | p<0,005 | 5,97468354 | 6,55696203 | 9,7％ |
| Mean value of deep breaths | p<0,005 | 6,79746835 | 7,24050633 | 6,5％ |
| Mean value of cough frequency | Is not significant | 1,56962025 | 1,55696203 | -0,8％ |
| Inflammation of the eye | p<0,005 | 1,3164557 | 0,92405063 | -29,8％ |
Thus, significantly better results have been obtained in the before-after-comparison for the following features: headache, nausea, health, free deep breathing, eye irritation, and work ability. For peripheral oxygen content determination, also better (higher) values of significance have been obtained.
While the values for the frequency of coughing were not different. This may be due to: the large content of substances just breaks down the dust substance and sputum and thus it is easier to trigger the attenuation process and this can be calculated more easily in the short term with more frequent coughs or less varying coughs frequency (like expectorants).
Thus, the data were branched off to completely positive results. Of particular advantage is the rise in the peripheral oxygen saturation as a well-defined physiological parameter ascertained with measurement techniques. SpO2 gives information about the oxygen load of the red blood cells and thereby finally also the supply of oxygen to the tissue. It is believed that an improvement has occurred.
Claims (27)
1. A nutritional supplement, comprising:
(a) a mineral component comprising at least one physiologically digestible salt comprising:
-a cation selected from the group consisting of: calcium, cobalt, iron, potassium, copper, magnesium, manganese, molybdenum, vanadium and zinc; and
-an anion selected from the group consisting of: acetates, carbonates, chlorides, fluorides, gluconates, iodates, iodides, oxalates, oxides, phosphates, phosphonates, and sulfates; and
(b) a vitamin component comprising at least one vitamin selected from the group consisting of: vitamin a (retinol), vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B4 (adenine, choline), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B7 (biotin), vitamin B8 (adenosine phosphate), vitamin B9 (folic acid), vitamin B10 (p-aminobenzoic acid, mixture of vitamin B groups), vitamin B11 (folic acid), vitamin B12 (cobalamin), vitamin B13 (orotic acid), vitamin B14 (mixture of vitamin B10 and B11), vitamin B15 (pangamine), vitamin B16 (pyridoxine), vitamin B17 (mandelic acid), vitamin B22, vitamin BT (levocarnitine), vitamin BX (p-aminobenzoic acid), vitamin C (ascorbic acid), vitamin D (calcium ascorbate), vitamin D (calcium), Vitamin E (tocopherol), vitamin H (biotin), vitamin K (phylloquinone, menaquinone), vitamin Q (ubiquinone, coenzyme Q10) and their derivatives.
(c) A plant extract fraction comprising at least two different plant extracts, said plant extracts being extracts from plants or plant parts, respectively, selected from the group consisting of: echinacea, ginseng, green tea, elderberry, sage and grape skin.
2. The nutritional supplement of claim 1,
wherein the plant extract fraction comprises at least three different plant extracts, each of which is an extract from a plant or plant part, independently of each other selected from the group consisting of: echinacea purpurea, ginseng, green tea, elderberry, sage and grape skin.
3. The nutritional supplement of claim 1 or 2,
wherein the plant extract component comprises ginseng extract and/or green tea extract and/or grape skin extract and/or echinacea extract and/or elderberry extract and/or sage leaf extract.
4. Nutritional supplement according to one of the preceding claims,
wherein the vitamin component comprises vitamin B2 and/or vitamin B2 derivatives and/or vitamin C and/or vitamin E derivatives and/or vitamin Q.
5. Nutritional supplement according to one of the preceding claims,
wherein the mineral component comprises a physiologically digestible zinc salt and/or magnesium salt and/or iron salt.
6. Nutritional supplement according to one of the preceding claims,
wherein the weight share of the plant extract component is in the range of 0.01 to 5.0 wt% based on the total weight of the nutritional supplement medicament.
7. The nutritional supplement of any of the above claims, further comprising:
(d) a sweet substance component comprising
-at least one carbohydrate selected from the group consisting of: sucrose, glucose syrup, invert sugar, fructose, and maltose; and/or
-at least one sweetener selected from the group consisting of: acesulfame K, alitame, aspartame-acesulfame K, sweet proteins, cyclamate, dulcin, hernandulcin, guanidinoacetic acid, monellin, neohesperidin, neotame, pentadin, saccharin, sucralose, stevioside, thaumatin; and/or
-at least one sugar substitute selected from the group consisting of: sorbitol, mannitol, isomalt, maltitol syrup, lactitol, xylitol and erythritol.
8. The nutritional supplement of claim 7,
wherein the weight share of the sweetener component is at least 50 weight percent based on the total weight of the nutraceutical.
9. The nutritional supplement of claim 7 or 8,
wherein the sweetener component comprises at least two carbohydrates and/or at least two sweeteners.
10. The nutritional supplement according to one of claims 7 to 9,
wherein the sweetener component comprises sucrose, maltose, aspartame and acesulfame potassium.
11. The nutritional supplement of any of the above claims, further comprising:
(e) an acidulant component comprising at least one carboxylic acid selected from the group consisting of: citric acid, tartaric acid and malic acid.
12. The nutritional supplement of claim 11,
wherein the acidulant component comprises citric acid.
13. The nutritional supplement of any of the above claims, further comprising:
(f) a perfume component comprising at least one perfume selected from the group consisting of: pineapple, apple, apricot (Marille), banana, pear, blackberry, strawberry, grapefruit, raspberry, cherry, kiwi, lemon, mango, citrus, melon, orange, papaya, passion fruit (Maracuja), peach, plum, quince, blackcurrant, gooseberry, tropical fruit, and lemon.
14. Nutritional supplement according to one of the preceding claims,
wherein the nutritional supplement is present as a powder.
15. The nutritional supplement according to one of claims 1 to 14, wherein,
(a) the mineral component comprises a physiologically digestible zinc salt; and/or
(b) Vitamin component
-vitamin B2 or a vitamin B2 derivative,
-vitamin C, and
-vitamin E or a vitamin E derivative;
and/or
(c) The plant extract component comprises Ginseng radix extract, green tea extract and grape skin extract; and/or
(f) The flavor component comprises tropical flavor.
16. The nutritional supplement of claim 15,
wherein, in each case, based on the total weight of the nutritional supplement,
-the weight fraction of physiologically digestible zinc salt is in the range of 0.033 ± 0.030 wt.%; and/or
-the weight share of vitamin B2 or vitamin B2 derivative is in the range of 0.0010 ± 0.0008 wt.%; and/or
-the weight fraction of vitamin C is in the range of 1.067 ± 1.000 wt.%; and/or
-the weight fraction of vitamin E or vitamin E derivative is in the range of 0.080 ± 0.070 wt.%; and/or
-the weight share of the ginseng extract is in the range of 0.167 ± 0.150 wt.%; and/or
-the weight share of green tea extract is in the range of 0.083 ± 0.080 weight%; and/or
-the weight fraction of the grape skin extract is in the range of 0.167 ± 0.150 wt%.
17. The nutritional supplement of claim 15 or 16,
wherein, in each case, the total content is based on: zinc salt, vitamin B2 or its derivative, vitamin C, vitamin E or its derivative, Ginseng radix extract, green tea extract and grape skin extract,
-the weight fraction of the physiologically digestible zinc salt is in the range of 2.1 ± 2.0 wt.%; and/or
-the weight share of vitamin B2 or vitamin B2 derivative is in the range of 0.10 ± 0.08 wt.%; and/or
-the weight fraction of vitamin C is in the range of 66.7 ± 50.0 wt.%; and/or
-the weight fraction of vitamin E or vitamin E derivative is in the range of 5.0 ± 4.0 wt.%; and/or
-the weight share of the ginseng extract is in the range of 10.4 ± 10.0 wt.%; and/or
-the weight share of green tea extract is in the range of 5.2 ± 5.0 wt.%; and/or
-the weight fraction of the grape skin extract is in the range of 10.4 ± 10.0 wt.%.
18. The nutritional supplement according to one of claims 15 to 17,
wherein, in each case, based on the total amount of the nutritional supplement drug set for administration,
-the physiologically digestible zinc salt is comprised in a dose in the range of 5.0 ± 4.0 mg; and/or
-vitamin B2 or a vitamin B2 derivative is comprised in a dose in the range of 0.21 ± 0.20 mg; and/or
-vitamin C is contained in a dose within the range of 160 ± 150 mg; and/or
-vitamin E or a vitamin E derivative is comprised in a dose in the range of 12 ± 10 mg; and/or
-the ginseng extract is contained in a dose within the range of 25 ± 24 mg; and/or
-the green tea extract is contained in a dose within the range of 12.5 ± 10 mg; and/or
-the grape skin extract is contained in a dose within the range of 25 ± 24 mg.
19. The nutritional supplement according to one of claims 15 to 18,
wherein the nutritional supplement is configured for consumption in the morning or configured for consumption in the morning.
20. The nutritional supplement according to one of claims 1 to 14, wherein,
(a) the mineral component comprises a physiologically digestible magnesium salt and a physiologically digestible iron salt; and/or
(B) The vitamin component comprises vitamin Q; and/or
(c) The plant extract components comprise Echinacea purpurea extract, elderberry extract and Salvia officinalis leaf extract; and/or
(f) The essence components comprise lemon essence and orange essence.
21. The nutritional supplement of claim 20,
wherein, in each case, based on the total weight of the nutritional supplement,
-the weight proportion of the physiologically digestible magnesium salt is in the range of 0.667 ± 0.600 wt.%; and/or
-the weight fraction of the physiologically digestible iron salt is in the range of 0.033 ± 0.030 wt.%; and/or
-the weight fraction of vitamin Q is in the range of 0.033 ± 0.030% by weight; and/or
-the weight share of the echinacea extract is in the range of 0.333 ± 0.300 wt%; and/or
-the weight share of elderberry extract is in the range of 0.480 ± 0.450 wt.%; and/or
-the weight share of the sage leaf extract is in the range of 0.333 ± 0.300 wt%.
22. The nutritional supplement of claim 20 or 21,
wherein, in each case, the total content is based on: magnesium salt, ferric salt, vitamin Q, Echinacea purpurea extract and Salvia officinalis leaf extract,
-the weight fraction of the physiologically digestible magnesium salt is in the range of 47.6 ± 45.0 wt.%; and/or
-the weight fraction of the physiologically digestible iron salt is in the range of 2.4 ± 2.0 wt.%; and/or
-the weight fraction of vitamin Q is in the range of 2.4 ± 2.0 wt.%; and/or
-the weight share of the echinacea extract is in the range of 23.8 ± 20.0 wt.%; and/or
-the weight share of the sage leaf extract is in the range of 23.8 ± 20.0 wt%.
23. The nutritional supplement according to one of claims 20 to 22,
wherein, in each case, based on the total amount of the nutritional supplement drug set for administration,
-the physiologically digestible magnesium salt is comprised in a dose in the range of 100 ± 80 mg; and/or
-the dose comprised of the physiologically digestible iron salt is in the range of 5.0 ± 4.0 mg; and/or
-vitamin Q is comprised in a dose in the range of 5.0 ± 4.0mg, more preferably in the range of 5.0 ± 3.2 mg; and/or
-echinacea extract is contained in a dose ranging from 50 ± 40 mg; and/or
-sage leaf extract is contained in a dose in the range of 50 ± 40 mg.
24. The nutritional supplement according to one of claims 20 to 23,
the nutritional supplement is configured for consumption at night or configured for consumption at night.
25. Nutritional supplement according to one of the preceding claims,
wherein the amount in each case set for consumption or set for administration is in the range of 5g to 100g, based on the total weight of the nutritional supplement medicament.
26. The nutritional supplement of claim 25,
wherein the amount is in the range of 5g to 25 g.
27. A package comprising at least one nutraceutical of one of claims 15 to 19 and at least one nutraceutical of one of claims 20 to 26.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE202016103333.0 | 2016-06-23 | ||
| DE202016103333.0U DE202016103333U1 (en) | 2016-06-23 | 2016-06-23 | Dietary supplements |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1253062A1 true HK1253062A1 (en) | 2019-06-06 |
Family
ID=58314236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18112444.7A HK1253062A1 (en) | 2016-06-23 | 2017-03-15 | Food supplement |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN107846954A (en) |
| DE (1) | DE202016103333U1 (en) |
| HK (1) | HK1253062A1 (en) |
| WO (1) | WO2017220220A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102020106691A1 (en) * | 2020-03-11 | 2021-09-16 | Pm-International Ag | Powdered composition for the manufacture of a drinkable product |
| WO2021191815A1 (en) * | 2020-03-26 | 2021-09-30 | Johnson & Johnson Consumer Inc. | Compositions comprising carum carvi and rosmarinus officinalis extracts and methods of using same |
| CN112915098A (en) * | 2021-03-30 | 2021-06-08 | 黑龙江中医药大学 | Medicine for relieving nausea and vomiting of pregnancy and preparation method thereof |
| GB202304518D0 (en) * | 2023-03-28 | 2023-05-10 | Nicoventures Trading Ltd | Oral product |
| GB202307279D0 (en) * | 2023-05-16 | 2023-06-28 | Nicoventures Trading Ltd | Oral product |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3160901A (en) * | 2000-01-11 | 2001-07-24 | Vitafood Ag | Dairy-free prebiotic instant powder which contains oligo-fructose |
| EP1228769A1 (en) * | 2001-02-02 | 2002-08-07 | Jörg-Peter Prof. Schür | Symbiotic regenerative composition |
| CN1255037C (en) * | 2003-09-28 | 2006-05-10 | 孙天民 | Nutritive tea and its preparing method |
| DE102004041270A1 (en) * | 2004-08-26 | 2006-03-02 | Merz Pharma Gmbh & Co. Kgaa | A capillary action system containing application differential differentiation compositions and their use |
| CN101141888A (en) * | 2004-12-14 | 2008-03-12 | 聪明燃烧制剂有限公司 | Supplemental dietary composition for promoting weight loss |
| UA12424U (en) * | 2005-01-28 | 2006-02-15 | Viktor Mykolaiovych Brechko | Phytotea composition "fitochai no.10" (phytotea no.10) |
| EP2066304B1 (en) * | 2006-09-05 | 2014-07-02 | Dental Biotechnology Ltd. | Echinacea, lavender, mastic gum and sage for treating halitosis |
| US20080254144A1 (en) * | 2007-04-16 | 2008-10-16 | Banayan Shahram A | Beverage health formulations |
| CN101428103A (en) * | 2008-11-17 | 2009-05-13 | 陈杨杨 | Formulation for treating senile dementia and Parkinsonismus |
| WO2011037618A2 (en) * | 2009-09-23 | 2011-03-31 | Todd Ehrlich | Dietary supplements in beverages or other forms, and methods of use and production |
| DE102011008478A1 (en) * | 2010-01-29 | 2011-08-04 | Müller-Schulte, Detlef, Dr., 52066 | Integral dietary supplement with a physiological efficiency, useful for preventing e.g. prostate disorders, malnutrition, osteoporosis, cardiovascular disease, cancer, comprises dried broccoli, dried vegetables and/or dried fruits |
| TW201204267A (en) * | 2010-05-24 | 2012-02-01 | Max International Llc | Compositions and beverages comprising nutrients, vitamins, sugars, cysteine, and/or sugar-cysteine products |
| CN101849971A (en) * | 2010-06-08 | 2010-10-06 | 玉溪健坤生物药业有限公司 | Soft capsule containing coenzyme Q10 and preparation method and application thereof |
| US20130224281A1 (en) * | 2011-04-07 | 2013-08-29 | United States Of America As Represented By The Administrator Of The National Aeronautics & Space | Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress |
| DE202011105533U1 (en) * | 2011-09-09 | 2011-12-05 | Globovita Gmbh | Vital substance composition according to Asian and Mediterranean nutritional concepts |
| JP2016513735A (en) * | 2013-03-15 | 2016-05-16 | マグシューティクス，インコーポレイテッド | Magnesium composition for cancer and uses thereof |
| DE202013002760U1 (en) * | 2013-03-21 | 2014-06-23 | Cc Pharma Gmbh | Dietary supplement for medication-oriented supplementation |
| WO2015014497A1 (en) * | 2013-08-02 | 2015-02-05 | Schweitzer-Mauduit International, Inc. | Edible product comprising reconstituted plant material |
| EP2974731A1 (en) * | 2014-07-18 | 2016-01-20 | Hennig Arzneimittel GmbH&Co. Kg | Administration form containing fungal components |
| DE202015102038U1 (en) * | 2015-04-24 | 2016-04-26 | Orthomol Pharmazeutische Vertriebs Gmbh | Caffeinated composition |
| DE102015009525A1 (en) * | 2015-07-17 | 2017-01-19 | Ulrich Jüstrich Holding AG | Novel compositions for use in premenopausal and menopausal women to provide improved nutritional supplementation and / or relief of menopausal symptoms |
| CN105494757A (en) * | 2015-12-11 | 2016-04-20 | 深圳市贝沃德克生物技术研究院有限公司 | Pure natural functional drink suitable for patient with chronic hepatitis B and preparation method thereof |
-
2016
- 2016-06-23 DE DE202016103333.0U patent/DE202016103333U1/en not_active Expired - Lifetime
-
2017
- 2017-03-15 HK HK18112444.7A patent/HK1253062A1/en unknown
- 2017-03-15 CN CN201780000736.0A patent/CN107846954A/en active Pending
- 2017-03-15 WO PCT/EP2017/056165 patent/WO2017220220A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN107846954A (en) | 2018-03-27 |
| DE202016103333U1 (en) | 2017-06-19 |
| WO2017220220A1 (en) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1253062A1 (en) | Food supplement | |
| CN106794214A (en) | Compositions containing mixtures of plant extracts or mixtures of molecules contained in said plants, and use for controlling carbohydrate and/or lipid metabolism | |
| US9149500B2 (en) | Method and process for relieving or preventing symptoms | |
| JP2007153888A (en) | Composition for purifying the body, food using the same, bathing agent, cosmetics, preparation and toxic metal excretion promoter | |
| MX2008010217A (en) | Microtablet-based pharmaceutical preparation. | |
| BR112019019405A2 (en) | use of a composition, antimicrobial composition, use or composition, pharmaceutical composition and therapeutic or non-therapeutic method | |
| US20060099239A1 (en) | Dietary supplement for promoting removal of heavy metals from the body | |
| Alburyhi et al. | Formulation, Development and Evaluation of Chamomile Extract Capsules Delivery System as an Advanced Phytotherapy Approach for Gout | |
| CN102596205B (en) | The application of stodgy oligosaccharide | |
| KR102598905B1 (en) | Deodorant composition comprising Quillaia saponaria | |
| White et al. | The herbal drugstore: the best natural alternatives to over-the-counter and prescription medicines! | |
| JP2012508772A (en) | Compositions and methods for mitigating reduced salivary secretion and providing oral comfort | |
| EP3873235B1 (en) | Phyto-therapyc compositions useful to improve the quality of sleep and in the treatment of insonnia, anxiety and depression | |
| JAAFAR et al. | The Use of Pharmaceutical Preparation of Phytosome Lepidium Sativum Extract as Anti-diarrheal Induced by the Bacteria E. coli in Mice. | |
| US20210212950A1 (en) | Orally deliverable formulation to prevent all cause mortality and cardiovascular events | |
| JP2014152147A (en) | Adjuvant for helicobacter pylori eradication therapy, and pharmaceutical composition and composition of foods and drinks using thereof | |
| CN115335042A (en) | Multicomponent composition comprising collagen, resveratrol and astaxanthin and its use for the treatment of tendinopathy | |
| US9597278B2 (en) | Compositions and methods for alleviating hyposalivation and for providing oral comfort | |
| WO2010075611A1 (en) | Composition comprising proanthocyanidin, proteolytic enzyme and aloe vera/agave species substance | |
| CN101085076A (en) | Chinese and Western medicine united sustained-release injection for preventing and controlling coccidiosis of rabbit and its preparation method | |
| RU2485965C2 (en) | Compartment-specific dual combination of herbal extracts of ginkgo biloba and ginseng | |
| KR101610894B1 (en) | Taste-masked granules containing vitamin C | |
| CN103610841A (en) | Method for treating stomatitis of bamboo rats | |
| AU2014322996B2 (en) | Cocoa polyphenols and their use in the treatment or prevention of eosinophilic esophagitis | |
| Bright et al. | Honey in the Management of childhood illnesses |